Pacific Biosciences (PacBio) shares plunged on August 9, 2025, while the S&P 500 increased. The company faced headwinds regarding Americas revenue and was discussing Revio and Vega placements.
2 reports, 1 independent
Updated Aug 9
Gone quiet
- Reports
- 2
- Developments
- 4
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pacific Biosciences (PacBio) shares plunged on August 9, 2025, while the S&P 500 increased. The company faced headwinds regarding Americas revenue and was discussing Revio and Vega placements.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- PacBio's stock performance was compared to the broader market, noting that a Spark chemistry upgrade improved Revio performance and the Vega platform opened new growth avenues.Sub-event
- MBRU is an early customer of PacBio's Revio technology, with Christian Henry serving as CEO of PacBio.Sub-event
PacBio shares plunged while S&P 500 increased; operational issues cited.1 source
PACB stock outperformed S&P 500, driven by estimate adjustments.1 source
Keep exploring
The entities involved
-
Pacific Biosciences
biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksPacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted loss per share of 13 cents in seco
- ZacksPacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know Pacific Biosciences of California (PACB) closed the most recent trading day at $1.50, moving +1.35% fr